Literature DB >> 21688134

Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.

Masafumi Takeda1, Tomoya Yamashita, Masakazu Shinohara, Naoto Sasaki, Hideto Tawa, Kenji Nakajima, Atsushi Momose, Ken-Ichi Hirata.   

Abstract

We have applied an imaging system of phase-contrast X-ray CT to the detection of atherosclerotic plaque components by means of the differences of tissue mass densities. In this study, we investigated the effect of the anti-platelet therapies, widely used for secondly prevention of cardiovascular events, on plaque stability and examined whether this novel technique could detect the changes of plaque components under the therapy. Apolipoprotein E-deficient mice were fed on high-cholesterol diet alone and either with 0.1% cilostazol or clopidogrel for 10 weeks. We assessed atherosclerotic lesion volumes and components at brachiocephalic artery by the phase-contrast X-ray CT imaging and histochemistry. The phase-contrast X-ray CT imaging could reveal that cilostazol and clopidogrel significantly decreased atherosclerotic lesion volumes at brachiocephalic artery (31.2% reduction in cilostazol group and 37.4% reduction in clopidogrel group), compared with control group. In addition, the mass densities calculated by this method revealed the anti-platelet treatment increased stable plaque areas including high collagen content, but decreased unstable plaque areas including lipid and macrophage content. These findings were confirmed by histological analyses. Real-time PCR analyses indicated that anti-platelets inhibited gene expressions of cytokines and adhesion molecules, such as IFNγ and ICAM-1. Anti-platelet therapies had a beneficial effect on plaque stability maybe due to anti-inflammatory actions. Phase-contrast X-ray CT imaging could quantify the plaque volume and qualify the plaque components affected by anti-platelet therapies. This novel phase-contrast X-ray CT imaging system could be a plausible method to detect the unstable plaque non-invasively in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688134     DOI: 10.1007/s10554-011-9910-6

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  25 in total

1.  Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Authors:  Tomofumi Takaya; Seinosuke Kawashima; Masakazu Shinohara; Tomoya Yamashita; Ryuji Toh; Naoto Sasaki; Nobutaka Inoue; Ken-ichi Hirata; Mitsuhiro Yokoyama
Journal:  Atherosclerosis       Date:  2005-09-12       Impact factor: 5.162

2.  Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.

Authors:  Jacek Jawien; Gabor Csanyi; Mariusz Gajda; Lukasz Mateuszuk; Magdalena Lomnicka; Ryszard Korbut; Stefan Chlopicki
Journal:  Eur J Pharmacol       Date:  2006-11-15       Impact factor: 4.432

3.  Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.

Authors:  Jeong Hyun Lee; Goo Taeg Oh; So Youn Park; Jae-Hoon Choi; Jong-Gil Park; Chi Dae Kim; Won Suk Lee; Byung Yong Rhim; Yung Woo Shin; Ki Whan Hong
Journal:  J Pharmacol Exp Ther       Date:  2005-02-25       Impact factor: 4.030

Review 4.  Atherothrombosis and high-risk plaque: part I: evolving concepts.

Authors:  Valentin Fuster; Pedro R Moreno; Zahi A Fayad; Roberto Corti; Juan J Badimon
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

Review 5.  Medical treatment of peripheral arterial disease.

Authors:  Graeme J Hankey; Paul E Norman; John W Eikelboom
Journal:  JAMA       Date:  2006-02-01       Impact factor: 56.272

6.  The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Petra Keul; Markus Tölle; Susann Lucke; Karin von Wnuck Lipinski; Gerd Heusch; Mirjam Schuchardt; Markus van der Giet; Bodo Levkau
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-12-07       Impact factor: 8.311

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation.

Authors:  So Youn Park; Jeong Hyun Lee; Chi Dae Kim; Won Suk Lee; Won Sun Park; Jin Han; Yong-Geun Kwak; Ki Young Kim; Ki Whan Hong
Journal:  J Pharmacol Exp Ther       Date:  2006-03-17       Impact factor: 4.030

Review 9.  The molecular mechanisms of the thrombotic complications of atherosclerosis.

Authors:  P Libby
Journal:  J Intern Med       Date:  2008-05       Impact factor: 8.989

10.  Phase-contrast X-ray computed tomography for observing biological soft tissues.

Authors:  A Momose; T Takeda; Y Itai; K Hirano
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

View more
  8 in total

1.  Quantitative assessment of changes in carotid plaques during cilostazol administration using three-dimensional ultrasonography and non-gated magnetic resonance plaque imaging.

Authors:  Mao Yamaguchi; Makoto Sasaki; Hideki Ohba; Kiyofumi Mori; Shinsuke Narumi; Noriyuki Katsura; Kazumasa Ohura; Kohsuke Kudo; Yasuo Terayama
Journal:  Neuroradiology       Date:  2012-01-21       Impact factor: 2.804

2.  An initial evaluation of analyser-based phase-contrast X-ray imaging of carotid plaque microstructure.

Authors:  A A Appel; C-Y Chou; J C Larson; Z Zhong; F J Schoen; C M Johnston; E M Brey; M A Anastasio
Journal:  Br J Radiol       Date:  2013-01       Impact factor: 3.039

Review 3.  Cardiovascular imaging 2012 in the International Journal of Cardiovascular Imaging.

Authors:  Hiram G Bezerra; Ricardo A Costa; Johan H C Reiber; Frank J Rybicki; Paul Schoenhagen; Arthur A Stillman; Johan De Sutter; Nico R L Van de Veire; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2013-04       Impact factor: 2.357

Review 4.  Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.

Authors:  Sven Nylander; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2016-02-24       Impact factor: 8.739

5.  Analyzer-based phase-contrast x-ray imaging of carotid plaque microstructure.

Authors:  Alyssa A Appel; Cheng-Ying Chou; Howard P Greisler; Jeffery C Larson; Sunil Vasireddi; Zhong Zhong; Mark A Anastasio; Eric M Brey
Journal:  Am J Surg       Date:  2012-11       Impact factor: 2.565

6.  Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

Authors:  R H Olie; P E J van der Meijden; H M H Spronk; H Ten Cate
Journal:  Handb Exp Pharmacol       Date:  2022

7.  Dynamic changes and associated factors of clopidogrel resistance in patients after cerebral infarction.

Authors:  Bo Rong Zhou; Hong Ting Shi; Rong Wang; Min Zhang; Hai Tao Guan; Zi Fan Liu; Yan Hua Deng
Journal:  J Neurol       Date:  2013-10-18       Impact factor: 4.849

8.  Translation of atherosclerotic plaque phase-contrast CT imaging from synchrotron radiation to a conventional lab-based X-ray source.

Authors:  Tobias Saam; Julia Herzen; Holger Hetterich; Sandra Fill; Marian Willner; Marco Stockmar; Klaus Achterhold; Irene Zanette; Timm Weitkamp; Ulrich Schüller; Sigrid Auweter; Silvia Adam-Neumair; Konstantin Nikolaou; Maximilian F Reiser; Franz Pfeiffer; Fabian Bamberg
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.